Sientra (Sientra) Retained Earnings : $-731.79 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sientra Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sientra's retained earnings for the quarter that ended in Sep. 2023 was $-731.79 Mil.

Sientra's quarterly retained earnings declined from Mar. 2023 ($-707.54 Mil) to Jun. 2023 ($-717.02 Mil) and declined from Jun. 2023 ($-717.02 Mil) to Sep. 2023 ($-731.79 Mil).

Sientra's annual retained earnings declined from Dec. 2020 ($-558.86 Mil) to Dec. 2021 ($-621.34 Mil) and declined from Dec. 2021 ($-621.34 Mil) to Dec. 2022 ($-694.65 Mil).

Sientra Retained Earnings Historical Data

The historical data trend for Sientra's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sientra Retained Earnings Chart

Sientra Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Retained Earnings

Get a 7-Day Free Trial

-362.10

-468.92

-558.86

-621.34

-694.65

Sientra Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Retained Earnings	Get a 7-Day Free Trial															-672.67	-694.65	-707.54	-717.02	-731.79

Sientra Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Sientra (OTCPK:SIENQ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Sientra (Sientra) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sientra Inc (OTCPK:SIENQ) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

S0Z0:Germany

Address

3333 Michelson Drive, Suite 650, Irvine, CA, USA, 92612

Website

https://www.sientra.com

Sientra Inc is a part of the healthcare sector in the United States. Its business involves the provision of silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. Its operating segments are Breast Products and miraDry. The Breast Products segment focuses on sales of breast implants, tissue expanders and scar management products under the brands OPUS, AlloX2, Dermaspan, Softspan, and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System and bioTips. Geographically, the firm generates a majority of its revenue from the United States.

Executives

Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Ronald Menezes	director, officer: President and CEO	420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Van Hove Caroline F.	director	420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Oliver Christian Bennett	officer: General Counsel and VP	420 S. FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Andrew C Schmidt	officer: Chief Financial Officer	1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Irina Erenburg	director	420 S. FAIRVIEW AVENUE, SANTA BARBARA CA 93117
Nori Ebersole	director	C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Valerie J Miller	officer: VP, Controller and Interim CFO
Paul Sean Little	officer: Chief Financial Officer	SIENTRA, INC., 420 SOUTH FAIRVIEW AVENUE, SUITE 200, SANTA BARBARA CA 93117
Jeffrey M Nugent	director	1875 SOUTH GRANT STREET, SUITE 110, SAN MATEO CA 94402
Keith J Sullivan	director	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher	director	C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
Timothy Haines	director, 10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Philippe Schaison	director	C/O ACTAVIS PLC MORRIS CORP CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054